BTG3 and systemic lupus erythematosus: Like in pristane‐induced SLE mice, ARA290 treatment greatly reduced the serum levels of ADA and ANA (Figure 5B), decreased the glomerular size and cellularity in kidney (Figure 5C), improved the kidney functions (Figure 5D, E) and improved the bodyweight (Figure 5F) in the MRL/lpr SLE mice.